title: [Stomach lymphoma].
abstract: BACKGROUND
  Primitive gastric lymphoma (PGL) is a rare tumour, and although its incidence is rising it is difficult to state the role of the various therapeutic methods in treating this disease. Aim of this study is to point out what sequence of treatment is more effective trying to find out some guidelines which can be useful in clinical practice.
  
  
  METHODS
  Retrospective analysis of clinical data of 54 patients with PGL admitted at a University surgical department during 10 years. All the patients underwent neoadjuvant or adjuvant chemotherapy and D2 gastrectomy. Follow-up ranged from 6 to 120 months. Survival was related to: Mushoff's stage of disease, the grade according to the Working Formulation and the sequence of treatment. Statistical analysis was performed by Kaplan-Maier method and the difference between survival curves was compared by log-rank test.
  
  
  RESULTS
  Mean postoperative hospital stay was 12 days and morbidity was 18%. Five and 10 years overall survival rates were 70 and 85%. There was a significant difference in survival between patients with high grade PGL and those with intermediate grade (p=0.0188) as well as in those with low grade (p=0.0435). Patients in stages IE-II1E had a significantly longer survival than those in stages IIIE-IVE (p=0.0123). Patients in stages IE-II1E underwent neadjuvant chemotherapy and surgery and survived longer than those in whom surgery preceded chemotherapy (p=0.0293) instead for patients in stages IIIE-IVE neoadjuvant chemotherapy shortened survival (p=0.0403).
  
  
  CONCLUSIONS
  In personal opinion, in patients in stages IE-II1E chemotherapy should be carried out before surgery, while in those in stages IIIE-IVE the reverse scheme is more effective in achieving longer survival rates.
authors.affiliation: Divisione di Clinica Chirurgica Generale I, Ospedale San Gerardo, II Università di Milano, Bicocca, Monza, Milan, Italy.
authors.forename: C M
authors.initials: CM
authors.lastname: Franciosi
authors.forename: C
authors.initials: C
authors.lastname: Angelini
authors.forename: C
authors.initials: C
authors.lastname: Mussi
authors.forename: P
authors.initials: P
authors.lastname: Sartori
authors.forename: F
authors.initials: F
authors.lastname: Romano
authors.forename: S
authors.initials: S
authors.lastname: De Fina
authors.forename: F
authors.initials: F
authors.lastname: Uggeri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D013274:Stomach Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate